Skip to main content
Premium Trial:

Request an Annual Quote

CMD Names Potential Distributors for Cancer Dxs

Premium

CombiMatrix Molecular Diagnostics is talking to both Laboratory Corporation of America and Quest Diagnostics, as well as a "few others" as potential customers or distributors of its cancer molecular diagnostics, PGX Reporter learned this week.

According to CombiMatrix vice president Bret Undem, CMD hopes to obtain clinical laboratory improvement amendment (CLIA) certification by the end of the year, which is when it plans to have its first microarray-based diagnostic products ready.

The first three products, all based on CombiMatrix's CustomArray microarray technology, will focus on the diagnosis of lymphoma, melanoma, and the identification of tumors of unknown origin. Undem declined to comment on the "exact competitive advantage" of CMD's tests over those of others, for example a microarray gene expression profile for tumors of unknown origin developed by Arcturus Bioscience. Asked whether Arcturus and its partners would be a potential competitor, Undem said "I leave that up to you to decide."

Last week, CMD said it hired three new executives “(see Pharmacogenomics Reporter 5/26/2005), two coming from US Pathology Labs, which was purchased by LabCorp at the end of last year. Together with CEO Matt Watson and COO Dave Baunoch, this brings the number of former US Labs managers at CMD to four.

CMD also recently moved into US Labs' old lab space, sub-leased from LabCorp, in Irvine, Calif. The company currently has 10 employees and plans to add another five or so by the end of the year, according to Undem.

Filed under

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.